Investor Relations

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMRTSX:TKM) is a leading RNA interference (RNAi) therapeutics company. With more than 14 years of industry experience, Tekmira has established itself as a global leader in the RNAi field. Tekmira has a diverse pipeline of product candidates in development to treat serious human diseases such as cancer and viral infections like Hepatitis B and Ebola. The company is advancing the development of novel drugs in areas where there is a significant unmet medical need and commercial opportunity. Tekmira also licenses its leading LNP delivery technology to partners around the world.

View all »   RSSRecent Releases

Aug 20, 2014
Tekmira's Lipid Nanoparticle (LNP) Technology Targeting Marburg Virus Highlighted in Scientific Publication

Aug 13, 2014
Tekmira Provides Corporate Update and Announces Second Quarter 2014 Results

View all »Events & Presentations

Aug 13, 2014 at 2:00 PM PT
Tekmira Corporate Update and Q2 Results

May 21, 2014
The 17th Annual Meeting of the American Society of Gene and Cell Therapy